CONGENITAL CARDIOLOGY TODAY

Timely News and Information for BC/BE Congenital/Structural Cardiologists and Surgeons

Volume 10 / Issue 8 August 2012 North American Edition

IN THIS ISSUE

FDA Clearance of Cardiac Devices for Children: A Primer and Call to Action by Robert H. Beekman, III, MD ~Page 1

The Archiving Working Group of the International Society for Nomenclature of Paediatric and Congenital Heart Disease: A Visual Encyclopedia Illustrating the Terms and Definitions of the International Paediatric and Congenital Cardiac Code by Jorge M Giroud, MD; Vera D. Aiello, MD; Diane E. Spicer, BS; Robert H. Anderson, BSc, MD, FRCPath ~Page 8

Use of a Standardized Approach to Evaluation of Pediatric Chest Pain: Does it Make a Difference? by Brian M. Cardis, MD ~Page 11

Image of the Month - August 2012 - Presented by The Archiving Working Group

Contributors: Vera D. Aiello, MD; Robert Anderson, MD; Jorge M. Giroud, MD; Diane E. Spicer, BS ~Page 14

DEPARTMENTS

Medical News, Products and Information ~Page 16

> **UPCOMING MEDICAL MEETINGS** See website for additional meetings

ESC (European Society of Cardiology) Congress 2012 Aug. 25-29, 2012; Munich, Germany www.escardio.org/congresses/esc-2012/

2012 Specialty Review in Pediatric Cardiology Board Review/ CME Course Sep. 10-14, 2012; Chicago, IL USA www2.aap.org/sections/cardiology/ pediatric_cardiology/2012/

Southeastern Pediatric Cardiovascular Society (SEPCS) Conference 2012 Sep. 13-15, 2012; Atlanta, GA USA www.sepcs.org

Recruitment Ads on Pages: 4, 5, 6, 10, 16 and 18 Practice for Sale on Page: 17

FDA Clearance of Cardiac Devices for Children: A Primer and Call to Action

By Robert H. Beekman, III, MD

Interventional pediatric cardiology and cardiac surgery are highly technical specialties that are dependent upon the availability of appropriate medical devices. However, because of the relative infrequency and diversity of cardiac disorders in children (relative to adult cardiovascular disease), very few devices have been designed and approved explicitly for pediatric cardiovascular applications.¹

Recent events have elevated the level of discourse concerning FDA device clearance processes. Using the Humanitarian Device Exemption (HDE) process, the FDA cleared the Melody Transcatheter Pulmonary Valve

"The purpose of this paper is to review current FDA processes for clearance of medical devices, to identify challenges posed to these processes by the fields of pediatric cardiology and cardiac surgery, and to propose possible solutions to these challenges."

(Medtronic) in 2010, and the EXCOR VAD (Berlin Heart) in late 2011. Nevertheless, some cardiologists and third-party payers persist in believing that these two devices are still experimental. Even more recently, concern has arisen around episodes of cardiac perforation in patients treated with the Amplatzer Septal Occluder (St. Jude) - a device cleared in 2001 when the FDA approved its Pre-Market Approval (PMA) application without a randomized clinical trial. If pediatric cardiologists and cardiac surgeons are to be effective advocates for children in need of improved access better cardiac devices, it is imperative that they understand the processes used by the FDA to clear devices for marketing.

The purpose of this paper is to review current FDA processes for clearance of medical devices, to identify challenges posed to these processes by the fields of pediatric cardiology and cardiac surgery, and to propose possible solutions to these challenges.

FDA Clearance of Medical Devices

The FDA Center for Devices and Radiological Health (CDRH) is responsible for assuring the safety and effectiveness of medical devices in the United States. The FDA clears a device for marketing and shipment across state lines (the FDA "clears" rather than "approves" medical devices). In general, FDA clearance is dependent upon a manufacturer providing sufficient data to support a claim of safety and effectiveness for an intended application of a given medical device.²

CONGENITAL CARDIOLOGY TODAY

CALL FOR CASES AND OTHER ORIGINAL ARTICLES

Do you have interesting research results, observations, human interest stories, reports of meetings, etc. to share?

Submit your manuscript to: RichardK@CCT.bz



A perfect melody of compassionate hearts, innovative minds and skilled hands.

Melody®

TRANSCATHETER PULMONARY VALVE (TPV) THERAPY

Worldwide, over 3,000 congenital heart disease patients have benefited from Melody TPV therapy. We remain committed to providing innovative options for your clinical management of these patients over their lifetime.

Visit www.Melody-TPV.com and restore hope for your patients.

Melody Transcatheter Pulmonary Valve Ensemble "Transcatheter Valve Delivery System Indications: The Nelody TPV is indicated for use in a dysfunctional Right Ventricular outflow Tract (RVOT) conduit when originally implanted) that is either regurgitant (> moderate) or stenotic (mean

Contraindications: None known Warnings/Precautions/Side Effects:

DO NOT imported autoins/bite Erects:
 DO NOT use if patient's anatomy precludes introduction of the valve, if the venous anatomy cannot accommodate a 22-Fr size introducer, or if there is significant obstruction of the central veins.
 DO NOT use if there are clinical or biological signs of infection including active endocarditis.

Assessment of the coronary artery anatomy for the risk of coronary artery compression should be performed in all
patients prior to deployment of the TPV.

To minimize the risk of conduit rupture, do not use a balloon with a diameter greater than 110% of the nominal diameter (original implant size) of the conduit for pre-dilation of the intended site of deployment, or for deploy ment of the TPV

The potential for stent fracture should be considered in all patients who undergo TPV placement. Radiographic assessment of the stent with chest radiography or fluoroscopy should be included in the routine postoperative evaluation of patients who receive a TPV

• If a stent fracture is detected, continued monitoring of the stent should be performed in conjunction with clinically appropriate hemodynamic assessment. In patients with stent fracture and significant associated RVOT obstruction or regurgitation, reintervention should be considered in accordance with usual clinical practice. Potential procedural complications that may result from implantation of the Melody device include: rupture of the RVOT conduit, compression of a coronary artery, perforation of a major blood vessel, embolization or migration of the device, perforation of a heart chamber, arrhythmias, allergic reaction to contrast media, cerebrovascular event: (TIA, CVA), infection/sepsis, fever, hematoma, radiation-induced erythema, and pain at the catheterization site. Potential device-related adverse events that may occur following device implantation include: stent fracture resulting in recurrent obstruction, endocarditis, embolization or migration of the device, valvular dysfunction (stenosis or regurgitation), paravalvular leak, valvular thrombosis, pulmonary thromboembolism, and hemolysis. For additional information, please refer to the Instructions for Use provided with the product or call Medtronic at 1-800-328-2518 and/or consult Medtronic's website at www.medtronic.com Melody and Ensemble are trademarks of Medtronic, Inc.

Humanitarian Device. Authorized by Federal law (USA) for use in patients with a regurgitant or stenotic Right Ventricular Outflow Tract (RVOT) conduit (≥16mm in diameter when originally implanted). The effectiveness of this system for this use has not been demonstrated.

Pathways for FDA Clearance of Medical Devices (3)

- 510(k) Application
- PMA (Premarket Approval) Application
- HDE (Humanitarian Device Exemption) Program

Figure 1.

Examples of Pediatric Cardiac Devices Receiving FDA Clearance without a Randomized Clinical Trial

- 510(k) Application
 - MReye Coil (Cook) 2009
 - Atlas Balloon Catheter (Bard) 2004
- PMA (Premarket Approval) Application
 - Amplatzer Duct Occluder (AGA Medical) 2003
 - Helex Septal Occluder (W.L. Gore) 2006
- HDE (Humanitarian Device Exemption) Application
 - Melody Transcatheter Pulmonary Valve (Medtronic) 2010
 - EXCOR VAD (Berlin Heart) 2011

Figure 2.

Currently there are three pathways for FDA clearance of medical devices (Figure 1):

- The 510 (K) application;
- The PMA (pre-market approval) application; and
- The HDE (humanitarian device exemption) application.

Each of these will be discussed in some detail below.

A. 510 (K) Application

The 510 (K) application provides the least-burdensome pathway to FDA clearance for manufacturers of medical devices. This pathway is used for lower risk (generally Class II) devices such as guidewires, coils, and infusion catheters. The 510 (K) application requires that a new device be "substantially equivalent" in intended use and device performance to a "predicate device" that is already on the market. The 510 (K) application typically does not require a manufacturer to submit clinical trial data in support of the application.

Examples of devices cleared by the 510 (K) mechanism include the MReye coil cleared in 2009 (Cook), the Atlas balloon dilation catheter cleared in 2004 (BARD) and the Gianturco-Grifka vascular occlusion device cleared in 1994 (Cook) (Figure 2).

Alternatives to Randomized Trials for Pediatric Cardiac Device Evaluation

- Performance goals (formerly "OPC")
- Use of contemporaneous, non-randomized controls (even from different institutions)
- Use of registry data
- OUS data
- Requirement for a robust post-market study (2007 legislation granted the FDA regulatory authority to mandate follow-up safety studies after initial market clearance)

Figure 3.

B. PMA (Pre-Market Approval) Application

A PMA application is the most common mechanism used by industry to obtain FDA clearance for marketing of a new medical device. The PMA pathway is used for higher risk (Class III) devices such as septal occluders, vascular occluders, coronary artery stents and implantable defibrillators. Of the three FDA pathways (Figure 1), a PMA application requires the most rigorous data demonstrating device safety and effectiveness. A manufacturer typically is required to submit bench, animal and clinical trial data in support of a PMA application. Clinical data are obtained under an FDA-approved Investigational Device Exemption (IDE) protocol. Classically, these protocols have been randomized clinical trials, considered the gold standard for generating safety and effectiveness data in support of a PMA application.

However, randomized clinical trials are exceedingly difficult to accomplish in pediatric cardiology and cardiac surgery. In fact, it is exceptional to find any randomized trials of pediatric cardiac devices in the literature.³ The challenges to successful randomized trials in pediatric cardiology and cardiac surgery are well-known. Congenital cardiovascular malformations are uncommon and exceedingly diverse in nature. Affected patients vary widely in size, often are expected to grow substantially after a device is implanted, and have life expectancies measured in decades (in contrast to the shorter life expectancies of many adult cardiac patients). Thus, it is exceedingly difficult to design adequately-powered randomized clinical trials for relevant pediatric cardiac devices. Moreover, the relative small numbers of pediatric cardiac patients limit market potential for industry and provide only small incentives for investment in research and development of devices targeted for this population.

Importantly, alternatives to the randomized clinical trial (RCT) design have been developed and used successfully for evaluation of pediatric cardiac devices (Figure 3). Performance Goals (PGs; formerly known as "objective performance criteria" or OPC's) are defined measures of device safety and effectiveness that are obtained from the literature and expert opinion. Performance Goals can be used to judge the performance of an investigational device, and serve as an alternative to data obtained from a randomized control group. Another alternative to the RCT is the use of contemporaneous but non-randomized control subjects (even from different institutions) to compare to subjects receiving the investigational device. Other alternatives to the RCT include the use of existing registry data, or data obtained from studies outside of the United States. Finally, pediatric device clearance can be



Opportunities available in all facets of Pediatric Cardiology

HCA, the largest healthcare company in the US, owns and/or manages over 160 hospitals in 20 states. We have opportunities available for Pediatric Cardiologists, Cardiovascular Surgeons and specialties associated with Pediatric Cardiology in most of our markets.

Whether you are looking for your first position or somewhere to complete your career, chances are we have something that will fit your needs. Call or email today for more information.



Kathy Kyer Pediatric Subspecialty Recruitment Manager Kathleen.Kyer@HCAHealthcare.com 937.235.5890 tied to a requirement that the manufacturer perform a robust postapproval study to evaluate longer-term device safety and effectiveness. The 2007 Pediatric Medical Device Improvement and Safety Act (PUB L N0. 110-85) granted authority to the FDA to mandate follow-up safety studies after initial market clearance.

There are several examples in the last decade of pediatric cardiac devices receiving PMA clearance from the FDA without a RCT. For example, the Amplatzer Duct Occluder (AGA Medical) received FDA PMA approval on May 14, 2003. The pivotal clinical study relied upon formal Performance Goals rather than control data from a RCT. An advisory panel to the FDA recommended the use of the following Performance Goals:⁴

- > 85% complete PDA closure at 12 months;
- > 95% clinical closure at 12 months; and
- major adverse event rate < 6%.

The FDA also required a five year post-approval study of the Amplatzer Duct Occluder.

The Helex Septal Occluder (W.L. Gore) provides another example of a pediatric cardiac device receiving PMA clearance without a RCT. The pivotal clinical study used historical and contemporaneous surgical control data obtained from non-randomized cases at the same institutions that implanted the investigational device.⁵ The pivotal study demonstrated device non-inferiority in a composite clinical outcome measure at 12 months. The Helix device was cleared by the FDA with PMA approval on August 11, 2006. The FDA also required a five year post-approval study be performed.

C. HDE (Humanitarian Device Exemption) Application

An HDE application provides a pathway to FDA clearance for devices used to treat "rare" disorders that affect fewer than 4,000 patients in the United States annually. This clearance process was developed in recognition of the difficulty of performing adequately-powered trials in small patient populations, with uncommon disorders and limited treatment options. Clinical trials of patients with such "rare" disorders are unable to generate safety and effectiveness data as robust as trials performed in patients with more common conditions. Consequently, HDE clearance by the FDA is based on evidence demonstrating:

- 1. Safety, and
- 2. Probable Benefit.

Because of the small number of patients available to participate in these trials, an HDE is exempt from showing "proof of effectiveness" as is required for a PMA application.

An approved HDE application authorizes the manufacturer to market the device. Furthermore, the 2007 Pediatric Medical Device Improvement and Safety Act permits the manufacturer to earn a profit for HDE-cleared devices for children. Because an approved HDE is based on less robust data than a PMA, there is a requirement that each institution's IRB approve the use of the device. Nevertheless, this does not imply that an HDE-cleared device is investigational.

Recently, two important cardiac devices for pediatric use have been cleared by the FDA using the HDE process (Figure 2). The Melody Transcatheter Pulmonary Valve (Medtronic) was cleared by an HDE



Mayo School of Continuous Professional Development and Co-sponsored by Children's Hospital of Orange County **Pediatric Cardiology 2012 Review Course**

August 26-31, 2012; The Ritz-Carlton, Laguna Niguel - Dana Point, California

REGISTER ONLINE TODAY: www.mayo.edu/cme/cardiovascular-diseases-2012r636

PEDIATRIC CARDIOLOGY OPPORTUNITIES AT CHILDREN'S HOSPITAL OF PITTSBURGH OF UPMC



The Division of Cardiology at Children's Hospital of Pittsburgh of UPMC / University of Pittsburgh School of Medicine is recruiting for the following Pediatric Cardiology faculty positions:

- Pediatric Heart Failure and Transplant Cardiologist to join the world-renowned pediatric transplant program
- **Non-Invasive Imaging Cardiologists** to join a large non-invasive imaging program. Completion of a 4th year non-invasive imaging fellowship is preferred.
- Outreach / General Pediatric Cardiologists to support an expanding ambulatory and outreach cardiology program.

The Heart Institute provides comprehensive pediatric and adult congenital cardiovascular services to the tri-state region and consists of 18 pediatric cardiologists, 4 pediatric cardiothoracic surgeons, 5 pediatric cardiac intensivists and 8 cardiology fellows along with 12 physician extenders and a staff of over 100.

Children's Hospital of Pittsburgh of UPMC has been named to *U.S. News & World Report's* 2012-13 Honor Roll of Best Children's Hospitals, one of only 12 hospitals in the nation to earn this distinction. Consistently voted one of America's most livable cities, Pittsburgh is a great place for young adults and families alike.

The positions come with a competitive salary and faculty appointment commensurate with experience and qualifications at the University of Pittsburgh School of Medicine. The University of Pittsburgh is an Equal Opportunity/ Affirmative Action Employer. Interested individuals should forward letter of intent, curriculum vitae and three (3) references. Informal inquiries are also encouraged.



Vivek Allada, MD

Clinical Director, Division of Pediatric Cardiology Children's Hospital of Pittsburgh of UPMC One Children's Hospital Drive 4401 Penn Avenue Faculty Pavilion, Floor 5 Pittsburgh, PA 15224 Telephone: 412-692-5411 E-mail: Vivek.Allada@chp.edu application approved by the FDA on January 25, 2010. The pivotal clinical data submitted in support of the Melody HDE application was a prospective, non-randomized evaluation of 99 subjects which assessed procedural success, safety and six-month effectiveness without a control group. The FDA also considered data submitted from outside the United States on a 68 patient cohort submitted by Dr. Philipp Bonhoeffer. The FDA approval of the Melody HDE application also included a requirement for two post-approval studies evaluating the device to a five-year endpoint. The first study included the patients from the initial IDE study, and the second was based on enrollment of 100 new patients also followed for five years.

The EXCOR Pediatric VAD (Berlin Heart) was cleared for marketing by the FDA when its HDE application was approved on December 16th, 2011. The EXCOR Pediatric VAD was evaluated in a prospective pivotal trial which was a multicenter study of 48 children at imminent risk of death from heart failure and who were listed for transplantation. Historical control data were obtained from the existing ELSO Registry of patients supported on ECMO between 2000 and 2007, and matched for age, weight and primary diagnosis with the EXCOR-supported patients. The FDA considered clinical data on 136 children supported on EXCOR at non-study sites in the United States, under a compassionate use protocol. The FDA also reviewed data on more than 100 patients from outside the United States. Finally, as part of the HDE approval, the FDA required that Berlin Heart perform a post-approval study to evaluate whether EXCOR safety and outcomes in the commercial setting are comparable to those reported in the pivotal study.

Next Steps: A Call To Action

The recent FDA clearance of the Medtronic Melody Valve and the Berlin Heart EXCOR VAD are important achievements for the health and welfare of children with serious cardiovascular disease. Neither device could be studied in a population large enough to support a robust RCT to support a PMA application, and therefore both devices were cleared for marketing by the FDA using the HDE pathway. *Nevertheless, important obstacles exist that block access to HDE-cleared devices for some children who need them.* These fundamentally derive from the nature of the HDE approval process itself, and specifically from:

- 1. the exemption from "proof of effectiveness" and
- the IRB requirement -- both of which were incorporated into the HDE process by the FDA because of the difficulty studying small patient populations with uncommon disorders.

There appears to be poor understanding of the HDE process by some individual IRBs and third-party payers. For example, I recently obtained a confidential draft of a "policy statement" from one of the largest health insurance companies in the United States. This draft was dated July 14, 2011, a full 18-months after the FDA granted clearance to Medtronic to market the Melody Valve. In this "policy statement," the company reviewed existing data and noted that published literature consists of relatively small case series with evaluation of short-term outcomes only. It concluded, therefore, the device remains investigational. Importantly, the "policy statement" noted that there were no available practice guidelines or formal position statements from professional organizations to draw upon. Patients insured through this company, and there are many, currently are denied coverage for implantation of the Melody Valve.

ongenital Heart Association

PEDIATRIC HEART FAILURE/ TRANSPLANT CARDIOLOGIST OPPORTUNITY



The Departments of Pediatrics at the University of Louisville School of Medicine and Kosair Children's Hospital are recruiting for a medical director of heart failure and cardiac transplantation for the Congenital Heart Center at Kosair Children's Hospital in Louisville, Ky.

The primary responsibilities for this position focus on directing and expanding current clinical programs in pediatric heart failure and transplantation to include collaborating with very successful clinical programs in adult heart failure, mechanical assist devices and transplantation. The Kosair Charities Pediatric Heart Research Program at the Cardiovascular Innovation Institute in Louisville and a broad array of basic science research programs at the University of Louisville provide outstanding research infrastructure and collaborative opportunities, with active programs in basic science and translational research involving tissue engineering, stem cells and ventricular assist devices.

An excellent multi-year compensation package is available, commensurate with expertise. Contact Christopher L. Johnsrude, M.D., chief of pediatric cardiology, at **cljohn02@louisville.edu** or (502) **852-3876**, or Amanda R. Bailey, physician recruitment manager, Norton Physician Services, at (502) **439-5144** or **amanda.bailey@nortonhealthcare.org**.







Kosair Children's Hospital (a part of Norton Healthcare) and the University of Louisville are Affirmative Action, Equal Opportunity, Americans with Disabilities employers, committed to diversity. In that spirit, we seek applications from a broad variety of candidates.

ACHA - 6757 Greene Street, Suite 335 - Philadelphia, PA, 19119 P: (888) 921-ACHA - F: (215) 849-1261

A nonprofit organization which seeks to improve the quality of life and extend the lives of congenital heart defect survivors.

http://achaheart.org

Next Steps to Improve Access to HDE-Cleared Devices

Pediatric Cardiologists, Cardiac Surgeons, and Affiliated Organizations should develop <u>Policy Statements and Practice</u> <u>Guidelines</u> to help educate 3rd parties that.¹

- HDE is <u>the</u> FDA mechanism to clear devices used for uncommon disorders (<4000 patients/year in the U.S.)
- An HDE-cleared device is approved for marketing, and the manufacturer can earn a profit on such devices for children
- An HDE-cleared device is <u>not investigational</u>

Figure 4.

These observations, particularly that there are no existing practice guidelines or position statements from medical societies to guide third party payers, strongly suggests some next steps to help increase access to current HDE-cleared devices (Figure 4). Pediatric cardiologists, cardiac surgeons and affiliated organizations should develop policy statements and practice guidelines to help educate third party payers of the following facts:

- HDE is the only FDA mechanism for clearance of devices used for uncommon disorders (< 4,000 patients per year in the United States);
- An HDE-cleared device is approved for marketing, and the manufacturer can earn a profit on such devices for children;
- An HDE-cleared device is not investigational.

Since the 2007 Pediatric Medical Device Improvement and Safety Act became law, the FDA has come a long way in its understanding of the unique challenges posed to device approval by pediatric cardiology and cardiac surgery. The relatively rare and diverse cardiac conditions that affect children are not amenable to evaluation in large randomized trials. Fortunately, the FDA recognizes these challenges and offers the HDE pathway as a mechanism to clear such devices for marketing. However, an apparent lack of understanding by third-party payers of the HDE clearance process has led to denial of coverage to families whose children stand to benefit from these devices. This situation creates a call to action for pediatric cardiologists and cardiac surgeons to lead the way in educating the public and third-party payers that HDE-cleared devices are truly approved and should be widely available to the children who need them.

References

- Sutherall JS, Hirsch R, Beekman RH. Pediatric Interventional Cardiology in the United States Is Dependent On the Off-Label Use of Medical Devices. Congenital Heart Disease 2010; 5:2-7.
- 2. Beekman RH, Duncan BW, Hagler DJ, Jones TK, Kugler JD, Moore JW, Jenkins KJ. Pathways to Approval of Pediatric Cardiac

"Since the 2007 Pediatric Medical Device Improvement and Safety Act became law, the FDA has come a long way in its understanding of the unique challenges posed to device approval by pediatric cardiology and cardiac surgery. The relatively rare and diverse cardiac conditions that affect children are not amenable to evaluation in large randomized trials."

Devices in the United States: Challenges and Solutions. Pediatrics 2009:E155-162.

- Bergersen L, Gauvreau K, Justino H, Nugent A, Rome J, Kreutzer J, Rhodes J, Nykanen D, Zahn E, Latson L, Moore P, Lock J, Jenkins K. Randomized Trial of Cutting Balloon Compared with High-Pressure Angioplasty for the Treatment of Resistant Pulmonary Artery Stenosis. Circulation 2011; 124(22):2388-2396.
- Multiorganizational Advisory Panel to PDA for Pediatric Cardiovascular Devices: Proposed Standards for Clinical Evaluation of Patent Ductus Arteriosus Occlusion Devices. Catheterization and Cardiovascular Interventions 2000; 51:293-296.
- Jones TK, Latson LA, Zahn E, Fleishman CE, Jacobson J, Vincent R, Canter K. Results of the U.S. Multicenter Pivotal Study of the HELEX Septal Occluder for Percutaneous Closure of Secundum Atrial Septal Defects. JACC 2007; 49:2215-2221.



Children's

Heart Center CARDIOLOGY



Robert H. Beekman, III, MD The Heart Institute of the Cincinnati Children's Hospital Medical Center 3333 Burnet Ave. Cincinnati, OH 45229-3026 USA Phone: 513-636-7072 Fax: 513-636-2410

Robert.Beekman@cchmc.org

REGISTER NOW FOR THE 45TH

Southeast Pediatric Cardiology Society Conference

www.eply.com/sepcs2012ce or (404) 785-7744

September 13–15, 2012

Atlanta, Georgia

The Archiving Working Group of the International Society for Nomenclature of Paediatric and Congenital Heart Disease: A Visual Encyclopedia Illustrating the Terms and Definitions of the International Paediatric and Congenital Cardiac Code

By Jorge M Giroud, MD; Vera D. Aiello, MD; Diane E. Spicer, BS; Robert H. Anderson, BSc, MD, FRCPath

"Classifications are theories about the basis of natural order, not dull catalogues compiled only to avoid chaos." ~ Stephen Jay Gould (1989)¹

Introduction

The urge to name and classify is part of the scientific legacy of human history. Cardiac malformations have been described throughout the centuries, with descriptions of various cardiac malformations such as ectopia cordis, septal defects, single ventricle and others, many written as case reports.² In 1858, Peacock published 'On Malformations of the Human Heart', in which he grouped the various forms of cardiac defects based on a combined anatomical and embryologic classification.³ Advances made during the late 19th, and early 20th, century reflected the increasing interest in congenital heart disease, with the descriptions of malformations by authors such as Fallot, Ebstein and Eisenmenger.⁴ In 1936, following the advice of Osler to treat the subject "statistically," Abbott published the 'Atlas of Congenital Cardiac Disease,' in which she offered a list of over a thousand congenital cardiac lesions.5

Throughout much of the 20th century, nonetheless, the classification of pediatric cardiac disorders remained fragmented, inconsistent, and in many circumstances based on historical considerations and eponyms. It was not always constructed from logic, nor the best available scientific evidence. As these limitations became apparent, groups of experts in the field of pediatric cardiology, cardiac surgery, morphology, and pathology offered two systems of nomenclature. These were published almost simultaneously in 2000.

One system was the nomenclature of the International Congenital Heart Surgery Nomenclature and Database Project of the European Association for Cardio-Thoracic Surgery (EACTS) and the Society of Thoracic Surgeons (STS). The second system of nomenclature was The European Paediatric Cardiac Code, produced on behalf of the Association for European Paediatric Cardiology (AEPC). It was quickly recognized that these systems, although slightly different in their main structure, were complementary. Thus, in October 2000, the International Nomenclature Committee for Paediatric and Congenital Heart Disease was created to reconcile these systems of nomenclatures. Fortunately, both of these systems were comprised of short and long lists. The initial result was the creation of a bidirectional cross-map of the short lists, which was presented at the First International Summit on Nomenclature for Congenital Heart Disease, held at the *Third World Congress of Paediatric Cardiology and Cardiac Surgery* in Toronto, Canada in May, 2001.

Four years later, the cross-map expanded to include the long lists. Now named the International Paediatric and Congenital Cardiac Code (IPCCC), it was presented at the Second International Summit on Nomenclature for Pediatric and Congenital Heart Disease, held at the Fourth World Congress of Pediatric Cardiology and Cardiac Surgery in Argentina, in September, 2005.⁶ The most recent version of the IPCCC was presented at the Third International Summit on Nomenclature for Pediatric and Congenital Heart Disease, held at the Fifth World Congress of Paediatric Cardiology and Cardiac Surgery in Australia, in June, 2009.⁷

The IPCCC is the responsibility of The International Society for Nomenclature of Paediatric and Congenital Heart Disease (ISNPCHD), which evolved from The International Nomenclature Committee for Paediatric and Congenital Heart Disease, and was incorporated in Canada in January, 2005.^{6,7} The goal of the ISNPCHD is "to standardize and maintain an international nomenclature system to enhance global communication and facilitate patient care, teaching, and research into paediatric and congenital heart disease across disciplines."⁸

The ISNPCHD is composed of three working groups.^{6,7,9} The oldest of the working groups is the International Working Group for Mapping and Coding of Nomenclatures for Paediatric and Congenital Heart Disease, also known as the Nomenclature Working Group (NWG). Currently, the NWG has cross-mapped the nomenclature of the International Congenital Heart Surgery Nomenclature and Database Project of EACTS and STS with the EPCC of AEPC. In addition, cross maps have been provided to the Fyler Codes of Boston Children's Hospital and Harvard University, the International Statistical Classification of Diseases and Related Health Problems of the World Health Organization

(ICD-9, ICD-10), the Current Procedural Terminology (CPT), and Canadian Congenital Heart Disease Codes. In 2007, to complement the efforts of the NWG, the ISNPCHD created two additional committees or working groups. These are the International Working Group for Defining the Nomenclatures for Pediatric and Congenital Heart Disease, also known as the Definitions Working Group (DWG), and The International Working Group for Archiving and Cataloguing the Images and Videos of the Nomenclatures for Pediatric and Congenital Heart Disease, better known as the Archiving Working Group (AWG). The mission of the NWG is to continue to maintain, preserve, and update the IPCCC. The DWG writes definitions for the terms in the IPCCC, building on the previously published definitions from the NWG. The purpose of the AWG is to link images of all types to the definitions provided by the DWG, and the codes developed by the NWG. The images and videos include photographs of gross anatomic specimens, echocardiograms, angiocardiograms, computerized axial tomographic and magnetic resonance images, as well as intraoperative photographs and videos. The AWG currently has an active image and video archive, called the AWG Web Portal (Figure 1), which can be viewed at http://ipccc-awg.net/.

The AWG Web Portal

The AWG management and workflow structure follows a process similar to that used in a peerreviewed publication. The identification of images and accompanying textual explanations, may be solicited or unsolicited. The members of the AWG project (Table 1), in particular the Senior Archivist, share in the responsibility of identifying suitable images that illustrate the various aspect of the codes and definitions of the IPCCC. The Senior Archivist, and the three Co-Chairpersons, work closely in the initial review and assignment of the codes and definitions of the images submitted. After the initial identification and assignment process is completed, a web page is modified or created, and the images, codes, definitions and explanatory text are posted to the AWG Web Portal (http://ipccc-awg.net). The initial publication of the images to the AWG Web portal is done with a 'pending' certification. Six times yearly, the members of the AWG review the posted images, codes, and text for accuracy, quality, and suitability. After this process is completed, the posted images, if approved, receive the official certification and



Figure 1. Archiving Working Group Website - http://ipccc-awg.net

rating, and the web page is updated to reflect the date of final approval.

The AWG Web Portal structure is a menudriven, unidirectional, navigational system based on the IPCCC Short Lists. To navigate the web site, the user selects from drop-down menus to reach the areas of interest. The user clicks on the image and code of interest to access the web page, where the codes, images, and explanatory texts are displayed. The images and videos reflect a variety of modalities, including photographs of autopsy or intra-operative specimens, clips of echocardiograms, angiocardiograms, computerized axial tomograms, and magnetic resonance studies. The contributions are catalogued and stored using industry standard formats. Although the images displayed may have copyright obligations, a feature of the AWG Web Portal is that the contributing author has given permission for the portal visitor to download the images, and to use them for notfor-profit, instructional, or educational purposes.

Conclusion

The Archiving Working Group of the International Society for Nomenclature of Paediatric and Congenital Heart Disease has created a web-based archive of representative images that visually define the codes and textual definitions of the International Paediatric and Congenital Cardiac Code.

The ISNPCHD has developed a system of nomenclature for multiple uses, including clinical, research, educational, and administrative purposes. The creation of a web-based visual 'encyclopedia' that illustrates the terms and definitions of the IPCCC helps to further this goal. It also adds the element of international inclusion, since the members of the AWG represent a cross section of the world's health care professionals interested in the cardiac diseases that affect children of all ages. Furthermore, the images and contributions to this project are open to all regardless of national or geographical origin. Please visit the AWG Web Portal (http://ipccc-awg.net/), and contribute your images and thoughts. We also invite you to review our 'Image of the Month' column, which debuts in this publication, and trust that you find it a valuable resource. We hope that this column becomes a part of your educational activities, and helps in furthering your understanding of the cardiac diseases which affect neonates, children, and increasingly adults with congenital cardiac disease.

References

 Gould, Stephen Jay (1989). Wonderful Life: The Burgess Shale and the Nature of History. New York: W. W. Norton & Co. Page 98.

Table 1: (Members of the Archiving Working Group)	
 Co-Chairpersons Vera D. Aiello (Cardiac Pathologist, Brazil) Robert H. Anderson (Cardiac Morphologist, UK & USA) Jorge M. Giroud (Pediatric Cardiologist, USA) 	Editorial Members • Carl Backer (CV Surgeon, USA) • Meryl Cohen (Pediatric Cardiologist, USA) • Andrew Cook (Cardiac Morphologist, UK) • Allen D. Everett (Pediatric Cardiologist, USA) • J. William Gaynor (CV Surgeon, USA) • Marina Hughes (Pediatric Cardiologist/MRI, UK) • Marshall L. Jacobs (CV Surgeon, USA) • Amy Juraszek (Pediatric Cardiologist, USA) • Otto N. Krogmann (Pediatric Cardiologist, Germany) • Hiromi Kurosawa (CV Surgeon, Japan) • Leo Lopez (Pediatric Cardiologist, USA) • Bohdan Maruszewski (CV Surgeon, Poland) • Giovanni Stellin (CV Surgeon, Italy) • Paul M. Weinberg (Pediatric Cardiologist/Morphologist, USA)
 ISNPCHD Executive Committee Christo I. Tchervenkov (CV Surgeon, Canada) (Chair) Marie J. Béland (Pediatric Cardiologist, Canada) Steven D. Colan (Pediatric Cardiologist, USA) Rodney C. G. Franklin (Pediatric Cardiologist, UK) Jeffrey P. Jacobs (CV Surgeon, USA) Henry Walters III (CV Surgeon, USA) 	Senior Archivist Diane Spicer (Cardiac Morphologist, USA)

- Rashkind WJ. Pediatric Cardiology: A Brief Historical Perspective. Pediatr Cardiology 1979; 1: 63-71.
- Porter IH. The Nineteenth-Century Physician and Cardiologist Thomas Bevill Peacock (1812-82). Med Hist. 1962 July; 6(3): 240–254.
- Ole Daniel Enersen, Whonamedit.com [http://www.whonamedit.com] 1994-2010. Accessed 30 April 2010.
 - E. L. A. Fallot: Contribution à l'anatomie pathologique de la maladie bleue (cyanose cardiaque). Marseille médical, 1888, 25: 77-93, 138-158, 207-223, 341-354, 370-386, 403-420.
 - b. W. Ebstein: Über einen sehr seltenen Fall von Insufficienz der Valvula tricuspidalis, bedingt durch eine angeborene hochgradige Missbildung derselben. Archiv für anatomie, Physiologie und wissenschaftliche Medicin, Leipzig, 1866, 238-254. Translation in American Journal of Cardiology, New York, 1968, 22: 867-872.
 - c. V. Eisenmenger: Die angeborenen Defecte der Kammerscheidewand des Herzens. Zeitschrift für klinische Medizin, 1897, 32 (Supplement): 1-28.
- Fraser R. Maude Abbott and the "Atlas of Congenital Cardiac Disease." Cardiovascular Pathology 2006;(15): 233– 235.
- Franklin RCG, Jacobs JP, Krogmann ON, Béland MJ, Aiello VD, Colan SD, Elliott MJ, Gaynor JW, Kurosawa H, Maruszewski B, Stellin G, Tchervenkov CI, Walters HL 3rd, Weinberg P, Anderson RH. Nomenclature for congenital and paediatric cardiac disease: Historical perspectives and The International Paediatric and Congenital Cardiac Code. Cardiol Young 2008; 18(Suppl. 2): 70–80.
- Giroud JM, Jacobs JP, Spicer D, Backer C, Martin GR, Franklin RC, Béland MJ, Krogmann ON, Aiello VD, Colan SD, Everett AD, Gaynor JW, Kurosawa H, Maruszewski B, Stellin G, Tchervenkov Cl, Walters HL, Weinberg P, Anderson RH, Elliott MJ.Report From The International Society for Nomenclature of Paediatric and Congenital Heart Disease: Creation of a Visual Encyclopedia Illustrating the Terms and Definitions of the International Pediatric and Congenital Cardiac Code.World Journal for Pediatric and Congenital Heart Surgery. 2010;1: 300-313.
- Constitution of The International Society for Nomenclature of Paediatric and Congenital Heart Disease (ISNPCHD). Rev: May 8, 2005. [http://ipccc.net], Accessed 6 June 2012.
- The International Society for Nomenclature of Paediatric and Congenital Heart Disease (ISNPCHD). [http://ipccc.net], Accessed 6 June 2012.

ССТ



Vera D. Aiello, MD Co-Chairman, Archiving Working Group Heart Institute (InCor). São Paulo University School of Medicine, Brazil



Robert H. Anderson, BSc, MD, FRCPath Co-Chairman, Archiving Working Group Institute of Medical Genetics Newcastle University, UK

Corresponding Contributor



Jorge M. Giroud, MD Co-Chairman, Archiving Working Group Congenital Heart Institute of Florida & Pediatrix Medical Group St. Petersburg & Tampa, USA jorgemgiroud@gmail.com



Diane E. Spicer, BS Senior Archivist, Archiving Working Group University of Florida, Department of Pediatrics-Cardiology, Gainesville, Florida Congenital Heart Institute of Florida St. Petersburg & Tampa, FL USA



The Children's Hospital of Illinois and University of Illinois College of Medicine at OSF Saint Francis Medical Center are Seeking Pediatric Cardiologists in Peoria and Rockford, Illinois

Peoria - The new pediatric cardiologist will join a well-established team of 7 pediatric Cardiologists with 30 plus years of success in the region. In addition to general pediatric cardiology, opportunities are focused on those interested in echocardiography, fetal echocardiography, and adult congenital heart disease. Professional components include inpatient rotation coverage, general cardiology clinic coverage and in-patient/out-patient echocardiography. Scholarly and research interests are highly desirable, along with experience in teaching medical students and residents. The candidate must be boardcertified or board-eligible in pediatric cardiology and will report to the Medical Director, Pediatric Cardiology.

Rockford - A BC/BE noninvasive pediatric cardiologist is desired to join 3 well established pediatric cardiologists in the Rockford branch of the Congenital Heart Center (CHC) system. The practice has been a stable source of quality pediatric cardiology care in the community for more than 20 years. The candidate should be skilled in all facets of echocardiography. Skills in fetal cardiology are desirable. The qualified individual will be part of the CHC which includes an additional 8 cardiologists at the Peoria campus. There is a direct clinical and academic relationship between the two groups.

The University of Illinois is an Affirmative Action/Equal Opportunity employer.

Stacey Morin, OSF Pediatric Cardiology CHOI Ph: 309-683-8354 or 800-232-3129 press 8; Fax: 309-683-8353 E-mail: stacey.e.morin@osfhealthcare.org Website: www.childrenshospitalofil.org

Use of a Standardized Approach to Evaluation of Pediatric Chest Pain: Does It Make a Difference?

By Brian M. Cardis, MD

Chest pain remains a common reason for referral to pediatric cardiologists. Despite a benign and non-cardiac etiology in the overwhelming majority of patients, this complaint continues to generate anxiety and fear of serious disease amongst patients and their families.^{1,2} In addition, overutilization of diagnostic testing by providers to rule out rare but serious underlying cardiac pathology has led to a significant increase in healthcare dollars spent. A recent study estimated \$3000 spent per patient in the outpatient evaluation of chest pain.³ Large retrospective studies of outpatient or emergency room evaluation of pediatric chest pain have only recently been reported.^{3,4}

Within our practice, thirty-six physicians evaluate approximately twothousand children annually with the chief complaint of chest pain. In October 2010, our practice instituted a standardized evaluation protocol (Figure 1) in an attempt to develop a comprehensive yet cost-effective method to identify cardiac causes of chest pain in children and to limit practice variability amongst physicians. Beginning in October 2010, all new patients evaluated in an outpatient clinic with a chief complaint of chest pain were required to complete a standardized "Chest Pain Questionnaire." This questionnaire included objective answers to descriptive questions regarding chest pain such as character, location, duration, associated symptoms, occurrence at rest or exercise, etc. Patients also completed a "Cardiac Risk Assessment Form" in order to identify risk factors for sudden cardiac death in the past medical or family history. A number of questions on both forms were arbitrarily identified by our group as "red flag" items, indicating potential for underlying cardiac disease. Completed forms were used in conjunction with electrocardiogram (performed on all patients) and physical examination. According to the protocol, abnormalities on the chest pain questionnaire, cardiac risk assessment form, electrocardiogram, or physical exam warranted further evaluation with echocardiogram. If abnormalities existed and there was compelling evidence of a non-cardiac cause of chest pain, the physician was allowed to deviate from protocol but was required to document why an echocardiogram was not performed.

A total of 2,416 patients were seen with a chief complaint of chest pain during the protocol period (October 2010-December 2011). Ages ranged from 2-26 years (median age of 13 years) with slightly more males than females (54.3 vs. 45.7%). Abnormal findings on either electrocardiogram or echocardiogram occurred in 98 patients (4%) (Table 1). Many of these were felt to be incidental findings in patients with a clear non-cardiac cause of chest pain. In fact, a cardiac etiology of chest pain was found in only 26 patients (1%) (Table 2). Further, potentially life-



Table 1: Abnormalities Found by EitherElectrocardiogram or Echocardiogram98/2416 total patients identified
 Patent Foramen Ovale (16) Premature Ventricular Contractions (15) Wolff-Parkinson-White syndrome (8) Atrial Septal Defect (8) Mitral Valve Prolapse (7) Bicuspid Aortic Valve (6) Premature atrial contractions (5) Pericardial effusion (4) Mild pulmonary stenosis (3) Idiopathic dilated aorta (3) Supraventricular tachycardia (3) Patent Ductus Arteriosus – small (3) Left Ventricular Noncompaction (2) Ventricular Septal Defect – small (2) Coronary Anomaly (2) Aortic valve disease (1) Hypertrophic Cardiomyopathy (1) Cleft Mitral Valve (1) Pericarditis (1) Coronary fistula (1) Right ventricular enlargement (1) Pulmonary hypertension – mild (1) Coarctation of the aorta (1)

threatening causes of chest pain were identified in only 17 patients (0.7%) and included: anomalous left coronary artery (n=1), anomalous right coronary artery (n=1), hypertrophic cardiomyopathy (n=1), Wolff– Parkinson-White Syndrome (n=7), mitral valve prolapse (n=6), and a combined finding of both Wolff-Parkinson-White syndrome and mitral valve prolapse (n=1). All 17 patients with potentially life-threatening cardiac disease had an abnormal physical examination or electrocardiogram.

A full cost analysis is currently in progress with results to be presented at the upcoming annual *Southeastern Pediatric Cardiology Society* (SEPCS) meeting in September. Preliminary analysis shows that echocardiogram was utilized in 1439/2416 (59.6%) of patients, an increase in usage when compared with patients evaluated prior to initialing the protocol (53.6%). Despite an overall increase in echocardiogram usage, this finding was not consistent throughout the group: 9/22 physicians who evaluated more than 20 patients with chest pain during the initial period had a lower utilization of echocardiogram after initiation of the protocol.

With the ultimate goal of identifying serious underlying cardiac pathology with minimal utilization of testing (echocardiogram), our group is currently working with the Georgia Institute of Technology to perform a detailed analysis of the chest pain questionnaire and cardiac risk assessment form. It is hoped that this will result in the ability to assign predictive values to each response with an eventual decrease in echocardiogram utilization. In addition, we are

Table 2: Cardiac Causes of Chest Pain 23/2416 patients (1%)

- Mitral Valve Prolapse (7)
- Supraventricular Tachycardia (5)*
- Atrial Septal Defect large (4)
- Pericardial Effusion (4)
- Coronary Anomaly (2)
- Hypertrophic Cardiomyopathy (1)
- Pericarditis (1)
- Coronary Fistula (1)
- Coarctation of the Aorta (1)

*Two patients with WPW were found to have SVT during subsequent electrophysiology study.

currently partnering with local pediatricians in order to adopt this protocol within the primary care setting. This may help to better select patients at risk for underlying cardiac conditions while eliminating unnecessary referrals for noncardiac chest pain.

To view the agenda or register for the *Southeastern Pediatric Cardiology Society* meeting, go to www.choa.org/sepcs.

References

- Driscoll DJ, Glicklich LB, Gallen WJ. Chest pain in children: a prospective study. Pediatrics 1976; 57(5): 648-51.
- 2. Pantell RH, Goodman Jr BW. Adolescent chest pain: a prospective study. Pediatrics 1983; 71(6): 881-7.
- Friedman KG, Kane DA, et.al. Management of pediatric chest pain using a standardized assessment and management plan. Pediatrics 2011; 128; 239-45.
- Drossner DM, Hirsh DA, et.al. Cardiac disease in pediatric patients presenting to a pediatric ED with chest pain. American Journal of Emergency Medicine 2011; 29: 632-38.

ССТ



Brian M. Cardis, MD Sibley Heart Center Cardiology / Children's Healthcare of Atlanta 1062 Forsyth St., Suite 3A Macon GA 31201 USA Phone: +1.478.743.4622

CardisB@kidsheart.com

GORE® HELEX® Septal Occluder

INDICATIONS FOR USE IN THE **US:** The GORE[®] HELEX Septal Occluder is a permanently implanted prosthesis indicated for the percutaneous, transcatheter closure of ostium secundum atrial septal defects (ASDs). INDICATIONS FOR USE UNDER **CE MARK:** The GORE[®] HELEX Septal Occluder is a permanently implanted prosthesis indicated for the percutaneous, transcatheter closure of atrial septal defects (ASDs). such as *ostium secundum* and patent foramen ovale. Refer to Instructions for Use at goremedical. com for a complete description of all contraindications, warnings, precautions and adverse events. $R_{\!X\,Only}$



Products listed may not be available in all markets. GORE®, HELEX®, and designs are trademarks of W. L. Gore & Associates. ©2011 W. L. Gore & Associates, Inc. AQ4872-EN1 DECEMBER 2011

Letters to the Editor

Congenital Cardiology Today welcomes and encourages Letters to the Editor. If you have comments or topics you would like to address, please send an email to: LTE@CCT.bz, and let us know if you would like your comment published or not.

Outcomes You Can Count On.

Save the Date! Webinar Review of FDA Circulatory System Devices Advisory Panel Meeting www.goremedical.com/HELEXWebinar

Rest assured knowing your patient is implanted with a GORE® HELEX® Septal Occluder.

High closure rates and low major adverse event rates demonstrated through clinical study data*

No reported erosions**

No reported late emergent surgical interventions**

* Results from the Feasibility, Pivotal, Continued Access, and Post-Approval Studies demonstrate 98.3% closure rate and a Major Adverse Event rate 45% at one year. Major Adverse Events were defined as any event requiring reintervention, readmission to the hospital, or resulted in permanent damage or deficit. ** Data on file.

W. L. Gore & Associates, Inc. • Flagstaff, AZ 86004 • goremedical.com

Products listed may not be available in all markets. GORE®, HELEX®, PERFORMANCE BY DESIGN, and designs are trademarks of W. L. Gore & Associates. ©2012 W. L. Gore & Associates, Inc. AR1432-EN1 JUNE 2012



PERFORMANCE by design

Image of the Month - August 2012 - Presented by The Archiving Working Group

Contributors: Vera D. Aiello, MD; Robert Anderson, MD; Jorge M. Giroud, MD; Diane E. Spicer, BS

This is a special column that will be published bimonthly in *Congenital Cardiology Today* with contributors and images from the Archiving Working Group (AWG) of *the International Society for Nomenclature of Paediatric and Congenital Heart Disease.*

Please visit us at the AWG Web Portal at http://ipccc-awg.net and help in the efforts of the Archiving Working Group and the International Society for Nomenclature of Paediatric and Congenital Heart Disease.



Figure 1. Description: This short axis view of the base of the heart shows the aortic and pulmonary valves. The aortic valve is bicuspid, with the attachments of the leaflets at the sinotubular junction marked with the yellow arrows. The right and left coronary arteries arise from separate sinuses. A raphe is present within the aortic sinus giving rise to the right coronary artery. The pulmonary valve is similarly bifoliate, and the valve is markedly stenotic. The white dots illustrate an area of fusion between two primordiums initially present during development, with the presence of an interleaflet triangle on the ventricular aspect supporting the notion of fusion during development. Contributor: Diane E. Spicer, BS



Figure 2. Description: The stenotic pulmonary valve is opened, demonstrating the thickened, nodular edges of the valve, along with the fused area (white dots) between two of the leaflets. The fused leaflets have been lifted to demonstrate the hypoplastic interleaflet triangle seen on the ventricular aspect (yellow lines). Note that this triangle is less well formed than the remaining two interleaflet triangles (black lines). The red arrows mark the attachment of the leaflets at the sinotubular junction. Contributor: Diane E. Spicer, BS

IPCCC: 09.15.22, 09.05.32, 01.03.10

AEPC Derived Term

- Bicuspid aortic valve (09.15.22)
- Bicuspid pulmonary valve (09.05.32)
- Normal atrial arrangement (situs), atrioventricular and ventriculo-arterial connections (01.03.10)

EACTS-STS Derived Term

- Aortic valve pathology, Bicuspid (09.15.22)
- Pulmonary valve pathology, Bicuspid (09.05.32)
- Normal atrial arrangement (situs), AV & VA connections (01.03.10)

ICD10 Derived Term

- Congenital stenosis of aortic valve (Q23.0)
- Congenital insufficiency of aortic valve: Bicuspid aortic valve (Q23.1)
- Other congenital malformations of pulmonary valve (Q22.3)

"This series of images from the same specimen illustrate the use of the interleaflet triangles as a means of recognizing the overall nature of valves with two leaflets, and also those with only one leaflet (the so-called unicommissural and unicuspid variant)."

Comments

This series of images from the same specimen illustrate the use of the interleaflet triangles as a means of recognizing the overall nature of valves with two leaflets, and also those with only one leaflet (the so-called unicommissural and unicuspid variant). These images illustrate the bifoliate nature of the pulmonary and aortic valves of this specimen. Please note that the presence of three attachments at the sinotubular junction does not mean that the valve is trifoliate. The number of leaflets should be determined on the pattern of opening and closing of the valve, and these valves can only open and close in bifoliate fashion, since it has a solitary zone of apposition within the skirt of leaflet tissue. It is usual to find interleaflet triangles in the setting of bifoliate valves, but only rarely is the arrangement both bifoliate and bisinuate! Thus, the presence of the interleaflet triangle does not disqualify the valve from being bifoliate.

"Can You Identify the Malformations in Figure 3 for the October Column? Hint: Look at the aortic arch and log on to AWG Web Portal at ipccc-awg.net."

For Further Information on the Subject Please Refer to These References:

- Angelini A, Ho SY, Anderson RH, Devine WA, Zuberbuhler JR, Becker AE, Davies MJ. The morphology of the normal aortic valve as compared with the aortic valve having two leaflets. J Thorac Cardiovasc Surg 1989;98:362367.
- Leung MP, McKay R, Smith A, Anderson RH, Arnold R. Critical aortic stenosis in early infancy. Anatomical and echocardiographic substrates of successful open valvotomy. J Thorac Cardiovasc Surg 1991;101:526535.

AWG Web Portal link for this series of images: http://ipccc-awg.net/ A o _ V a I v e _ D i s e a s e / Bicuspid_AO_PA_Valve_09_15_22/ Bicuspid_AO_PA_Valve_09_15_22.html.





Figure 3. Images for the October column: 'Identify the malformations.'

Can You Identify the Malformations in Figure 3 for the October Column?

The answers for the malformations in Figure 3 will appear in the October issue of *Congenital Cardiology Today* in this bimonthly column. Hint: Look at the aortic arch and log on to AWG Web Portal at ipccc-awg.net.

ССТ



Vera D. Aiello, MD Co-Chairman, Archiving Working Group Heart Institute (InCor). São Paulo University School of Medicine, Brazil



Robert H. Anderson, BSc, MD, FRCPath Co-Chairman, Archiving Working Group Institute of Medical Genetics Newcastle University, UK

Corresponding Contributor



Jorge M. Giroud, MD Co-Chairman, Archiving Working Group Congenital Heart Institute of Florida & Pediatrix Medical Group St. Petersburg & Tampa, USA jorgemgiroud@gmail.com



Diane E. Spicer, BS Senior Archivist, Archiving Working Group University of Florida, Department of Pediatrics-Cardiology, Gainesville, Florida Congenital Heart Institute of Florida St. Petersburg & Tampa, USA

Medical News, Products and Information

The NRG-56 Radiofrequency Transseptal Needle Receives FDA Clearance

MONTREAL, CANADA July 18, 2012 -- The NRGTM Transseptal Needle uses radiofrequency (RF) energy to cross the septum with control and predictability. The needle delivers RF through its rounded tip to create a small hole. This allows physicians to avoid using uncontrolled mechanical force.

The new NRG-56 Transseptal Needle is designed specifically for smaller patients. With the model number NRG-56-32-C0, it measures 56 cm in length and is compatibility with dilators that have an inner diameter of 0.032". Specifically, the NRG-56 is compatible with pediatric (6F) transseptal sheaths. The C0 represents the curve radius of the needle.

The NRG-56 provides the physician with added control when crossing the septum in patients with small left atrium which may reduce the risk of tamponade. Added to this, the radio-opaque market tip also allows the physician to be confident of the needle's exact tip position throughout the transseptal puncture procedure.

RF energy for transseptal puncture has also been shown to be effecting in crossing pericardial and Dacron patches.

Baylis Medical is a world leader in the development, manufacturing, and marketing of innovative radiofrequency systems with applications in Interventional Cardiology, Electrophysiology and Interventional Radiology. The Baylis Medical Radiofrequency (RF) Puncture system is designed specifically to safely and effectively create a puncture in tissues with minimal damage to surrounding tissues. The pediatric and adult applications include doing transseptal punctures, treating pulmonary atresia and re-canalizing peripheral vascular occlusions.

For more information, go to www.baylismedical.com.

Doctors Study Novel New Device to Diagnose Irregular Heartbeat

A study conducted at Scripps Health has found that a novel new heart monitoring device helped emergency room patients avoid unnecessary follow-up care. Scripps Health electrophysiologist Steven Higgins, MD, presented findings of the study titled, "Prevalence of Arrhythmias in Emergency Department Patients Discharged Using a Novel Ambulatory Cardiac Monitor", today at the *Heart Rhythm Society's 33rd Annual Scientific Sessions* in Boston.

The study focused on the use of Zio[®] Patch, a single-use ambulatory cardiac monitor that looks similar to a 2- by 5-inch adhesive bandage and sticks to a patient's chest, that continuously monitors their heart rhythm for up to 14 days.

"The availability of this new heart monitor is exciting as it improves patient care. The patch is applied and when recording is done, the patient simply drops it in the envelope and returns it to us – it's like the



Pediatric Cardiac Critical Care Physician Chicago Area

Advocate Medical Group (AMG), a physician-led multispecialty team of over 900 physicians, seeks an experienced board certified/board eligible Pediatric Cardiac Critical Care specialist to join The Heart Institute for Children at Advocate Hope Children's Hospital. Located in suburban Chicago this unique, thriving, dynamic clinical practice includes 16 Pediatric Cardiologists.

Position includes the opportunity to educate residents and fellows from multiple area institutions. The program has over 8000 clinic visits per year, 4500 on-site echocardiograms, 300 cardiac catheterizations, and 350-450 surgeries/year at our main campus alone. Our surgical group averages 700+ surgeries per year at multiple sites. Our outcomes are among the best in the nation. We have an accredited cardiology fellowship program with 6 fellows. We have a dedicated 9 bed Pediatric Surgical Heart Unit, an additional 15 bed Pediatric Intensive Care Unit, and a 4 bed step down unit.

Candidates must be BC/BE in Pediatric Cardiology or Pediatric Critical Care. Board Certification in both subspecialties is preferred but not required. This is an outstanding opportunity for the right individual who is interested in both cardiology and critical care. Additional training can be provided on-site dependent upon needs (with consideration for a fourth year training period for recent graduates). Numerous opportunities for research and professional growth exist. Excellent benefit package is offered.

It goes without saying that Chicago is indeed a wonderful place to live. It is a beautiful city that boasts a diverse cultural and historic background.

Interested candidates should send their resume to:

Donna C. Kutka, R.N., M.S. Director, Physician Recruitment 708.684.5009 donna.kutka@advocatehealth.com

Andrew Van Bergen, MD Director, Pediatric Cardiac Critical Care The Heart Institute for Children Advocate Hope Children's Hospital



6th WORLD CONGRESS Paediatric Cardiology & Cardiac Surgery 17 – 22 February 2013, Cape Town, South Africa South African Heart Congress 2013



Hosted by:

Netflix of heart care," said Dr. Higgins, Chairman of the Department of Cardiology at Scripps Memorial Hospital La Jolla and a lead investigator. "Because they are infrequent, heart rhythm problems are often difficult to diagnose, even though they can be quite serious. The Zio[®] Patch is a new digital advance that will allow us to better diagnose challenging cases so we can provide our patients the best care."

The study followed 285 patients who had presented to emergency departments across the country with symptoms possibly related to arrhythmias, such as fainting, palpitations, dizziness and others. Patients received the unencumbering, wire-free Zio® Patch prior to being discharged from the emergency room and were instructed to wear the patch until it no longer adhered to their skin – up to 14 days duration. Devices were mailed back to iRhythm Technologies, Inc., the Zio® Patch's developer and service provider, using a pre-paid postage envelope, for analysis and reporting of results to the patient's physician.

The researchers found that 59% of the symptomatic patients who presented to the emergency rooms did not have arrhythmia and may not require any further work-up. "Thus, the new device has the potential to save the health care system millions of dollars," said Higgins. "We were also surprised to learn that there was 100% compliance by the patient with the process, which is an amazing finding for an emergency department study."

Other study locations included Stanford Hospital and Scott & White Memorial Hospital in Temple, Texas.

Monitoring Leads to Possible Lifesaving Procedure

One patient who benefited from the Zio Patch is La Jolla resident, Kenneth Curzon, who fainted while at work in March. Curzon continuously wore the Zio Patch for two weeks and then mailed it back to iRhythm, where the information was downloaded and formatted into a report for Dr. Higgins to review.

The recording showed Curzon was experiencing prolonged pauses in his heart rhythm of over three seconds as well as other episodes of rapid heart beats. On April 6, he received an implantable cardiac defibrillator to correct the problem and was back to his management job within five days. "The Zio[®] Patch allowed me to diagnose and determine the most appropriate therapy for Ken," said Higgins.

Zio® Patch vs. Holter monitor

In addition, Dr. Eric Topol is leading a new related study at Scripps Green Hospital examining whether the Zio Patch does a better job of detecting heart arrhythmias than the Holter monitor, which has been the gold standard for rhythm monitoring since the early 1960s.

The portable Holter monitor collects its data through a series of wired electrodes that adhere to the chest. Because the device can be difficult to wear and can get in the way of normal activities such as showering, exercising and sleeping, continuous use of the monitor is typically limited to one or two days. In contrast, the Zio[®] Patch is a small, unobtrusive device that is indicated for up to 14 days of wear, and allows the patient to exercise and shower on their normal schedule, without the hassle of a bulky monitor and multiple wires.

"This is a great opportunity to compare these two side-by-side for use in diagnosing important heart rhythm disturbances," said Dr. Topol, a cardiologist who directs the Scripps Translational Science Institute and serves as Chief Academic Officer of Scripps Health. "We are trying to determine if the Zio Patch will have an increased diagnostic yield."

The study is currently enrolling about 150 Scripps Green and Scripps Clinic adult patients who have been seen by their doctors for arrhythmia. Each of the participants will wear a Holter monitor and a Patch for up to 48 hours and then continue wearing the Zio Patch for up to 14 days. More information about the study is available at www.clinicaltrials.gov.

Dr. Topol and his research associates will compare the data gathered from each device and report their findings later this year.

Both studies are an extension of Scripps Health's leadership in heart care and research. The institute will incorporate leading-edge wireless technologies and individualized medicine for the best in patient care when it opens in 2015.

More information can be found at www.scripps.org.

Pediatric Cardiology Practice for Sale

Well-established pediatric cardiology practice of 25 years in gulf region, is for sale. The physician/owner is planning to retire soon. Practice is continuing to grow with great potential to expand in multiples. Office is fully equipped with ECG, Echocardiogram, holter and stress test.

Collections have been consistently over \$500K, low overhead. Well-established and wide-based referral system is already in place, with great potential to grow in peripheral area. There are 2 NICU in the area. Invasive and interventional cath labs are available to pursue interest. 2 groups of perinatologists, all pediatric subspecialists including pediatric surgeon and intensivists in the area as support structure is in place.

Culturally rich area to raise family and great year round recreational facility, makes this a very attractive place to live. Area is economically very strong and growing with wide diversity. Great and diverse gastronomy is appealing to any palate!

Owner will stay on for some time to introduce new physician to referring physicians.

Please contact

Practice@CCT.bz



A BOARD REVIEW COURSE PRESENTED BY American Academy of Pediatrics Section on Cardiology & Cardiac Surgery — in collaboration with — Society of Pediatric Cardiology Training Program Directors

Discounts for early registration and AAP members available.

www.aap.org/sections/cardiology/pediatric_cardiology/2012

Pediatric Cardiology Division Chief

The Department of Pediatrics at the Wake Forest University School of Medicine (WFUSM) in Winston Salem, North Carolina, is recruiting a full-time section head (chief) for the division of Pediatric Cardiology. The ideal candidate will be a board certified cardiologist with training and experience in providing leadership, as well as clinical, academic and service excellence. The candidate should have already achieved the rank of associate or full professor, or be qualified for promotion to the rank of associate professor in the department of Pediatrics. In addition to proven leadership abilities, a strong record of research or academic success is required.

The Children's Heart Program at Brenner Children's Hospital functions as a service-line enterprise with support from the hospital administration. The chief of cardiology will be responsible for providing clinical oversight and supporting the academic growth of the current faculty of eight and will also function in collaboration with the director of the Children's Heart Program (one of the two CT surgeons, who is ABTS certified in congenital heart surgery), the vice-president of Brenner Children's Hospital, and the chair of the department of Pediatrics, to formulate the strategic vision for growth of the program. This is a major leadership position for our Children's Hospital and consequently, the successful candidate will receive appropriate support, including an opportunity to recruit other essential team members as needed and develop required programs. We want this important recruit to be successful in helping us achieve our strategic goals of becoming the recognized center of excellence for congenital heart care in Western North Carolina, as well as their own goals to be recognized as a successful leader in academic pediatric cardiology. An interest in and track record of teaching medical students, residents and fellows is required. We are in the process of submitting our PIF for a pediatric cardiology fellowship.

Winston Salem offers a lifestyle that is tough to beat...a short commute, low cost of living, excellent school choices, diverse cultural amenities...a wonderful place to live and raise a family. The city is home to Wake Forest University, one of the country's top academic institutions. We are conveniently located close to beautiful recreational lakes, just over an hour to the NC mountains and three to four hours to the Carolina beaches.

Wake Forest University Baptist Medical Center is an affirmative action and equal opportunity employer with a strong commitment to achieving diversity among its faculty and staff.

Interested candidates should contact:

Bill Selvey WilliamLaine, Inc. direct 404-495-9411, toll free 877-231-8379 bselvey@williamlaine.com



ACC and ACP Expand Performance Measures Detailed in PINNACLE-PC Registry To Provide Access to Primary Care Internists

The American College of Cardiology (ACC) and the American College of Physicians (ACP), announced in early June plans to launch a pilot program, PINNACLE Primary Care, that will expand the PINNACLE Registry to assess performance measures for primary care practices.

The PINNACLE Registry currently collects data from cardiology practices to calculate performance measures related to atrial fibrillation, hypertension, coronary artery disease and heart failure. Made up of more than 4.2 million patient encounters, PINNACLE is the nation's largest cardiovascular outpatient quality-improvement registry. PINNACLE Primary Care, which will be known as PINNACLE-PC, will measure performance on breast and colon cancer screenings, influenza and pneumonia immunizations, lower back pain, diabetes, depression, weight management, and chronic obstructive pulmonary disease.

The pilot will begin this summer with 5 to 10 internal medicine practices. Data from pilot practices will be collected through December 2012 and results will be analyzed in early 2013. If the pilot is successful, the ACC and ACP will make the PINNACLE Registry available to members of the American College of Physicians.

"Registries are excellent quality improvement tools," said ACC President Dr. William Zoghbi, MD, FACC. "Registry participants receive quick feedback that can help practices ensure that they are providing consistent, evidence-based care. Expanding the PINNACLE Registry to include primary care is a natural extension of this great resource, which will ultimately improve care."

"We are very enthusiastic about our collaboration with ACC and this program to test the PINNACLE Registry in primary care internal medicine practices," said ACP President David L. Bronson, MD, FACP.

ACC Senior Vice President of Science & Quality and PINNACLE Chair William J. Oetgen, MD, MBA, FACC, said expanding PINNACLE to primary care has been a goal for the registry since its inception.

The PINNACLE registry assists practices in understanding and improving care through the production and distribution of quarterly performance reports for data-submitting practices and physicians. The reports cover all valid patient encounters and detail adherence to 25 cardiovascular clinical measures at the physician, location, and practice levels across the diagnoses of coronary artery disease, hypertension, heart failure, and atrial fibrillation. Thirteen additional performance measures will be added to PINNACLE to create PINNACLE-PC.

As part of the National Cardiovascular Disease Registries (NCDR) suite, the PINNACLE Registry provides a centralized system for clinical practices to promote practice innovations and achieve clinical excellence.

Skewed Results? Failure to Account for Clinical Trials Drop-Outs Can Lead to Erroneous Findings

Newswise - A new University at Buffalo study of publications in the world's top five general medical journals finds that when clinical trials do



not account for participants who dropped out, results are biased and may even lead to incorrect conclusions.

Published recently in the *British Medical Journal*, the methodological study consisted of a systematic analysis of 235 clinical trials published in the world's top five general medical journals between 2005 and 2007 that claimed a statistically significant effect.

"We found that in up to a third of trials, the results that were reported as positive – in other words, statistically significant – would become negative – not statistically significant, if the investigators had appropriately taken into consideration those participants who were lost to follow-up," says Elie A. Akl, MD, MPH, PhD, lead author, and Associate Professor of Medicine, Family Medicine and Social and Preventive Medicine at the University at Buffalo School of Medicine and Biomedical Sciences and School of Public Health and Health Professions. He also has an appointment at McMaster University.

According to Akl, it has always been suspected, but never proven, that loss to follow-up introduces bias into the results of clinical trials. "The methodology we developed allowed us to provide that proof," he says.

The methodology that he and his coauthors developed consists of sensitivity analyses, a statistical approach to test the robustness of the results of an analysis in the face of specific assumptions, in this case, assumptions about the outcomes of patients lost to follow-up.

"This methodology will allow those who conduct the trials and those who use their results, including clinicians, other scientists, developers of clinical guidelines, policymakers and bodies like the Food and Drug Administration (FDA), to better judge the risk of bias," concludes Akl.

The studies that were analyzed had previously been published in *Annals* of *Internal Medicine, British Medical Journal, the Journal of the American Medical Association, Lancet* and the *New England Journal of Medicine*. To be included, the trials studied had to have reported a significant effect.

Akl led this major study, which took three years to complete. His coauthors are from the following institutions: McMaster University; University Hospital Basel; Kaiser Permanente Northwest; Hospital for Sick Children in Toronto; Institute for Work and Health, Universitè de Sherbrooke; University Children's Hospital Tuebingen; Pontificia Universidad Catolica de Chile; Tel Aviv University; the University of Ottawa; the University of Freiburg and the University of Oxford.

Children's National Medical Center and Baby's First Test Join Forces to Advance - Screening for Critical CHD in Newborns

The Children's National Medical Center and Baby's First Test released two videos on screening for critical congenital heart disease (CCHD) using pulse oximetry (pulse ox) in newborns. The videos, produced for parents and clinicians respectively, were designed to forward knowledge about the test. To view the videos, please visit www.ChildrensNational.org/pulseox or www.babysfirsttest.org.

CCHD screening is quickly becoming a standard of care across the country. Nine states have passed legislation surrounding CCHD screening of newborns, and many more have legislation or executive committees examining the implementation of the procedure. In

September 2011, CCHD screening was endorsed by the Department of Health and Human Services to be included in the recommended uniform screening panel for newborns in the U.S.

"The videos we are releasing today are essential to our efforts to educate parents and clinicians about critical congenital heart disease screening. We have learned that the pulse ox test can be used to identify newborns with CCHD before discharge from birthing facilities. We know that approximately 3 of every 1,000 babies born are affected by CCHD and early detection of serious forms of the disease may improve health outcomes for those babies," said Gerard Martin, MD, Senior Vice President of the Center for Heart Lung and Kidney at Children's National.

Baby's First Test, operated by the non-profit group Genetic Alliance, is the nation's newborn screening. Newborn screening (NBS) NBS can include a heel stick, hearing screen, and pulse oximetry. The conditions that newborn babies are screened for varies by state.

"We are thrilled to offer these videos to parents who want to understand what tests their babies are getting, and why; and to clinicians who want to learn more about the use of pulse ox in the newborn nursery," said Natasha Bonhomme, Director of Baby's First Test.

Baby's First Test, the nation's newborn screening information center, is dedicated to educating parents, health professionals, and the public about the newborn screening system. Baby's First Test provides information and resources about screening at the local, state and national levels. This initiative is funded through a cooperative agreement with the Genetic Services Branch of the Maternal and Child Health Bureau of the Health Resources Administration to Genetic Alliance, a 25-year old non-profit organization that seeks to improve health through the authentic engagement of communities and individuals.

CONGENITAL CARDIOLOGY TODAY

© 2012 by Congenital Cardiology Today (ISSN 1554-7787-print; ISSN 1554-0499-online). Published monthly. All rights reserved.

Corporate Offices: 8100 Leaward Way, Nehalem, OR 97131 USA Mailing Address: PO Box 444, Manzanita, OR 97130 USA Tel: +1.301.279.2005; Fax: +1.240.465.0692 Editorial and Subscription Offices: 16 Cove Rd, Ste. 200, Westerly, RI 02891 www.CongenitalCardiologyToday.com

Publishing Management:

- Tony Carlson, Founder, President & Sr. Editor TCarlsonmd@gmail.com
- Richard Koulbanis, Group Publisher & Editor-in-Chief RichardK@CCT.bz
- John W. Moore, MD, MPH, Medical Editor JMoore@RCHSD.org

Editorial Board: Teiji Akagi, MD; Zohair Al Halees, MD; Mazeni Alwi, MD; Felix Berger, MD; Fadi Bitar, MD; Jacek Bialkowski, MD; Philipp Bonhoeffer, MD; Mario Carminati, MD; Anthony C. Chang, MD, MBA; John P. Cheatham, MD; Bharat Dalvi, MD, MBBS, DM; Horacio Faella, MD; Yun-Ching Fu, MD; Felipe Heusser, MD; Ziyad M. Hijazi, MD, MPH; Ralf Holzer, MD; Marshall Jacobs, MD; R. Krishna Kumar, MD, DM, MBBS; John Lamberti, MD; Gerald Ross Marx, MD; Tarek S. Momenah, MBBS, DCH; Toshio Nakanishi, MD, PhD; Carlos A. C. Pedra, MD; Daniel Penny, MD, PhD; James C. Perry, MD; P. Syamasundar Rao, MD; Shakeel A. Qureshi, MD; Andrew Redington, MD; Carlos E. Ruiz, MD, PhD; Girish S. Shirali, MD; Horst Sievert, MD; Hideshi Tomita, MD; Gil Wernovsky, MD; Zhuoming Xu, MD, PhD; William C. L. Yip, MD; Carlos Zabal, MD

Statements or opinions expressed in Congenital Cardiology Today reflect the views of the authors and sponsors, and are not necessarily the views of Congenital Cardiology Today.



Archiving Working Group International Society for Nomenclature of Paediatric and Congenital Heart Disease

ipccc-awg.net

SIZING UP THE FUTURE



X^{TTM} Line PTV Balloon Dilatation Catheters Braided inner tubing and radiopaque marker bands for maintaining strength & trackability

PTS[®] Sizing Balloon Catheters For accurate measurement of selecting the appropriately sized occluder device

NuCLEUS-X[™] PTV Balloon Dilatation Catheters

Variable waist expansion in the center of the balloon for accurate placement

> The Center of It All

BBRAUN

B. Braun Interventional Systems Inc. 824 Twelfth Avenue Bethlehem, PA 18018 Tel: 1-877-VENA CAV (836-2228) Fax: 610-266-3982

Interventional

www.bisusa.org